(Reuters) -BioCryst Pharmaceuticals said on Tuesday it would buy Astria Therapeutics in a cash-and-stock deal valued at about $700 million, strengthening its rare diseases portfolio. The offer implies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback